ReviewJournal of nanobiotechnology2026
From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gene therapy has become a cornerstone of precision medicine, offering potential solutions for a wide spectrum of disorders at the molecular origin. However, the clinical performance of gene therapeutics is critically determined by the efficiency and safety of delivery vectors. Though viral vectors are widely used in gene therapy because of their high delivery efficiency, the safety concern remains a major limitation. In contrast, non-viral vectors have attracted increasing attention owing to their favorable safety profiles, structural tunability, larger cargo capacity, and scalable production. In this review, we examine five major classes of non-viral gene delivery vectors, including Lipid Nanoparticles (LNP), polyplexes, lipoplexes, and exosomes, together with their corresponding hybrid systems. For each platform, we summarize structural features, delivery mechanisms, therapeutic applications, and translational challenges, and further discuss how hybrid architectures integrate complementary properties from different vectors to overcome limitations inherent to single-component systems. By organizing these delivery strategies within a unified structure-function-application framework, this review provides an integrated perspective on non-viral vector design and highlights hybrid systems as an increasingly important direction for the optimization of clinically relevant gene delivery platforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.